Catch up on the latest imaging research presented at the recent American Society for Radiation Oncology (ASTRO) Annual Meeting.
|Articles|October 23, 1996
Abbott gains more rights to Sonus agent
Sonus Pharmaceuticals of Bothell, WA, has granted U.S. marketingpartner Abbott Laboratories licensing rights to its EchoGen ultrasoundcontrast agent in all international territories outside Japanand nine other Asia-Pacific countries. In exchange for the
Advertisement
Sonus Pharmaceuticals of Bothell, WA, has granted U.S. marketingpartner Abbott Laboratories licensing rights to its EchoGen ultrasoundcontrast agent in all international territories outside Japanand nine other Asia-Pacific countries. In exchange for the internationalrights, Abbott, of Abbott Park, IL, has agreed to make $34.6 millionin license and milestone payments, some of which will be creditedagainst future royalties.
Sonus and Abbott in May reached a pact covering EchoGen salesin the U.S. (SCAN 5/22/96). With this latest deal, Abbott gainsEchoGen marketing rights to additional territories, includingEurope, the rights to which Sonus regained from French contrastfirm Guerbet earlier this year (SCAN 9/11/96). Daiichi Pharmaceuticalhas marketing rights in Pacific Rim countries.
Sonus has filed a new drug application for EchoGen with theFood and Drug Administration and plans to file for European regulatoryapproval of the product by the end of this year.
Advertisement
Related to this article
Tightness of the high-convexity sulci (THC) on brain MRI was associated with nearly threefold higher odds of cognitive decline over five to seven years of follow-up, according to a new prospective study involving over 2,100 community-dwelling senior citizens.
An AI model for prostate MRI offered an 89 percent AUC for prostate cancer detection in external validation testing, according to a newly published international multicenter study.
In the latest episode of her Breast Imaging in Focus series, Manisha Bahl, MD, MPH, FSBI, discusses new research comparing mammography-based AI models for breast cancer detection and short-term risk prediction.
In a recent episode of our Molecular Imaging in Focus series, Jack Andrews, MD, discussed pertinent findings from a recent intra-patient comparative study of PSMA PET agents in men with recurrent prostate cancer presented at the recent ASTRO conference.
The use of adjunctive CT bone reading software in women with breast cancer detected between 8 to 22 percent more metastatic lesions for reviewing radiologists and reduced CT interpretation time by 50 percent or more, according to a new study.
Expert Radiology is a **radiologist-run teleradiology practice with 10 years of experience**, hiring teleradiologists earning **$500–$900/hr with per-dictation pay**. Work from anywhere with true flexibility, **no shifts, no call, and no weekends**.
Our case mix is **predominantly outpatient and noncontrast**, with approximately **75% MRI**, plus X-ray and CT.
We cover **malpractice with tail**, handle all medical licensing, and ship you a **$10K reading station with six vertical 4K monitors**.
Minimum commitment is an **average of 400 cases per month**.
**Book a call with Brandi Escapule, Principal, Physician Services.**
How will generative AI software be evaluated by the FDA in the future? What’s next for point-of-care ultrasound? What steps have been successful in facilitating adoption of AI applications across enterprise systems? Leaders in radiology and health care will be discussing these topics and more at the upcoming HLTH USA conference.
Advertisement
Advertisement
Trending on Diagnostic Imaging
1
What a Large Prostate MRI Study Reveals About AI and Unassisted Radiologist Assessment
2
Breast Imaging in Focus: Can AI Models for Breast Cancer Detection and Risk Prediction Be Used Interchangeably?
3
MRI Study Links Tightness of High-Convexity Sulci to Higher Risk of Cognitive Decline in Older Adults
4
Research Highlights from the ASTRO 2026 Annual Meeting
5